SLRX•benzinga•
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Says A Series Of Antiviral Drug Candidates Previously Designed By Its IMP3ACT Program Showed In Silico Activity Against Measles And Nipah Viruses
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 26, 2025 by benzinga